AMALIA Massively Scalable Platform for Dual-Mode Discovery of Anti-Amyloid Drugs
- Coordinator
- Fundacio Institut De Bioenginyeria De Catalunya, Spain
- Runs
- 1 May 2026 to 31 October 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101289202
What the project is doing
In the project's own words, from its summary on CORDIS.
Amyloids are protein aggregates that underlie Alzheimer’s, Parkinson’s, and other devastating diseases, yet effective therapies remain elusive. A key bottleneck is our limited ability to study and target the earliest steps of amyloid formation, which are difficult to probe with existing approaches and poorly suited for large-scale discovery. AMALIA addresses this gap by establishing a dual, massively scalable platform for anti-amyloid drug discovery, combining complementary assays that target aggregation through distinct mechanisms.
This project will validate AMALIA as a scalable and versatile platform for anti-amyloid drug discovery and downstream translation. Enabling parallel, cost-effective discovery across multiple amyloid targets, AMALIA has the potential to fundamentally change how anti-amyloid therapeutics are developed.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Institut De Bioenginyeria De Catalunya | Barcelona | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI